EMBARGOED FOR RELEASE: 3 P.M. (CT), WEDNESDAY, SEPTEMBER 3, 2014
Media Advisory: To contact corresponding author Susana Ortiz-Urda, M.D., Ph.D., call Elizabeth Fernandez at 415-514-1592 or email Elizabeth.Fernandez@UCSF.edu.
To place an electronic embedded link to this study in your story The link for this study will be live at the embargo time: http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2014.1077.
Bottom Line: Airline pilots and cabin crews appear to have twice the incidence of melanoma as the general population.
Author: Martina Sanlorenzo, M.D., of the University of California, San Francisco, and colleagues.
Background: Melanoma is a common cancer in the United States; in 2014, 76,100 people will be diagnosed with the skin cancer and 9,710 people will die. Several studies have suggested a higher incidence of melanoma in pilots and flight crew. Flight-based workers are thought to have a greater occupational hazard risk of melanoma because of increased altitude-related exposure to UV and cosmic radiation. While the risks of exposure to ionizing radiation for pilots and cabin crew are known and the levels regularly monitored, UV exposure is not a well-recognized occupational risk factor for the flight crew.
How the Study Was Conducted: The authors assessed the risk of melanoma in pilots and airline crew by reviewing medical literature. Their meta-analysis included 19 studies with more than 266,000 participants.
Results: The overall summary standardized incidence ratio (SIR) of melanoma for any flight-based occupation was 2.21, the summary SIR for pilots was 2.22 and 2.09 for cabin crew.
Discussion: “In this systematic review and meta-analysis including 19 studies and more than a quarter of a million participants, we found that the combined and separate SIRs for pilots and cabin crew were greater than the 2, indicating that pilots and air crew have twice the incidence of melanoma compared with the general population. … This has important implications for occupational health and protection of this population.”
(JAMA Dermatology. Published online September 1, 2014. doi:10.1001/jamadermatol.2014.1077. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: There are numerous funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.